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Abstract
Background: Clinical development of vaginally applied products aimed at reducing the transmission of HIV and other
sexually transmitted infections, has highlighted the need for a better characterisation of the vaginal environment. We set
out to characterise the vaginal environment in women in different settings in sub-Saharan Africa.
Methods: A longitudinal study was conducted in Kenya, Rwanda and South-Africa. Women were recruited into pre-defined
study groups including adult, non-pregnant, HIV-negative women; pregnant women; adolescent girls; HIV-negative women
engaging in vaginal practices; female sex workers; and HIV-positive women. Consenting women were interviewed and
underwent a pelvic exam. Samples of vaginal fluid and a blood sample were taken and tested for bacterial vaginosis (BV),
HIV and other reproductive tract infections (RTIs). This paper presents the cross-sectional analyses of BV Nugent scores and
RTI prevalence and correlates at the screening and the enrolment visit.
Results: At the screening visit 38% of women had BV defined as a Nugent score of 7–10, and 64% had more than one RTI (N.
gonorrhoea, C. trachomatis, T. vaginalis, syphilis) and/or Candida. At screening the likelihood of BV was lower in women
using progestin-only contraception and higher in women with more than one RTI. At enrolment, BV scores were
significantly associated with the presence of prostate specific antigen (PSA) in the vaginal fluid and with being a self-
acknowledged sex worker. Further, sex workers were more likely to have incident BV by Nugent score at enrolment.
Conclusions: Our study confirmed some of the correlates of BV that have been previously reported but the most salient
finding was the association between BV and the presence of PSA in the vaginal fluid which is suggestive of recent
unprotected sexual intercourse.
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Introduction
UNAIDS estimated that in 2012 0.5% and 0.3% of women and
men aged 15–24 years were living with HIV globally [1]. There
were, however, important regional differences with the highest
prevalence rates reported in sub-Saharan Africa, 2.5% and 1.2%
among young women and men, respectively. The high vulnera-
bility to HIV acquisition of young women in sub-Saharan Africa
compared to young men can be explained by a combination of
behavioural factors including patterns of age mixing; socio-cultural
factors and imbalances in gender power relations; and biological
factors. Among the latter, infection with herpes simplex virus-2
(HSV-2) and deviations from the normal lactobacilli dominated
vaginal microbiota take a prominent place [2–5]. For instance, in a
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cohort of HIV uninfected women in Uganda and Zimbabwe it was
estimated that 50% of incident HIV infections were attributable to
HSV-2 infection, 17% to bacterial vaginosis (BV) and 12% to
intermediate microbiota as defined by Nugent score [5].
Novel interventions addressing the vulnerability of young
women to HIV and other sexually transmitted infections (STIs)
are urgently needed. These will include vaginally applied products,
such as medicinal products containing antiretroviral drugs, and
‘multipurpose’ devices releasing antimicrobial compounds and
hormones to prevent reproductive tract infections and pregnancy
[6]. These innovative methods should also restore and/or
maintain a healthy vaginal environment with its innate defence
mechanisms. During clinical development of vaginally applied
products, it became clear that the vaginal environment needs to be
better characterised in order to establish a ‘baseline’ which can be
used to evaluate the effects of candidate vaginal products. Better
characterisation is not only needed in the ‘general population’ at
low or average risk of HIV, it is also needed in subpopulations that
are often targeted for reproductive health interventions, such as
adolescent girls, pregnant women, HIV-positive women, and
women at high risk of HIV infection.
In the research project entitled ‘‘Characterisation of novel
microbicide safety biomarkers in East and South Africa’’, we set
out to characterise the vaginal environment of a representative
sample of HIV negative adult women at low risk for HIV. The
vaginal environment was also studied in smaller sub-populations of
women in Kenya, South-Africa and Rwanda. The main aim of the
project was to characterise the vaginal microbiota, to describe the
mucosal immune responses in the vagina and to assess changes
over time. In this paper, we present the socio-demographic and
behavioural characteristics of the study populations, the preva-
lence of BV and reproductive tract infections (RTIs) and correlates
of BV and RTIs at screening and at enrolment in a cross-sectional
analysis.
Methods
Study design and population
Women were screened and enrolled in 2010–2011 at three
study sites: the International Centre for Reproductive Health
Kenya (ICRHK), Mombasa, Kenya; the Wits Reproductive
Health and HIV Institute (WrHI), Johannesburg, South Africa
(SA); and the non-governmental organisation Rinda Ubuzima
(RU), Kigali, Rwanda. Although this paper focuses on the cross-
sectional data from the screening and the enrolment visit,
participants were followed up for approximately eight months
per person. All women, eligible or not, were offered diagnostic
testing for RTIs at the screening visit. The results were evaluated
with the participants two weeks later when treatment was
provided. Enrolment of eligible participants was then scheduled
after the next menses (approximately day 9 of the menstrual cycle;
window of 2 days). A further description of the full study schedule
is available in Methods S1.
Women were recruited into per protocol predefined study
groups as follows: adult, non-pregnant, HIV-negative women at
average risk of HIV (referred to in this paper as the reference
group); pregnant women (up to 14 weeks gestation); adolescent
girls (16–17 years); HIV-negative women engaging in vaginal
practices; self-acknowledged female sex workers (FSW); and HIV-
positive women on antiretroviral treatment. The women in the
reference group and the pregnant women were recruited from
family planning clinics, ‘women’s groups’ and antenatal clinics in
Mombasa County and Johannesburg. Adolescent girls were
recruited at youth centres and youth-friendly family planning
services in Mombasa and Johannesburg. Women engaging in
vaginal practices were recruited in Johannesburg only. These
women used substances (cloth/lemon juice/detergents) other than
water and/or fingers to clean, dry or tighten the vagina on a
regular basis. FSW and HIV-positive women were recruited in
Kigali from the sex worker community, using community
mobilisers and from public HIV treatment clinics, respectively.
Participants were eligible for inclusion in the study if they were
in good physical and mental health; able and willing to participate
in the study as required by the protocol; able and willing to give
written informed consent (and written assent for minors), including
written parental/guardian consent for adolescents; and HIV-
negative unless confirmed HIV-positive for inclusion in the HIV-
positive women group. Pregnant women were included in the
study if they were up to 14 weeks gestational age as defined by
abdominal ultrasound. HIV-positive women were included if they
had been on antiretroviral treatment for at least 6 months, were
asymptomatic and had a CD4 count of more than 350 cells/ml.
Participants meeting one or more of the following criteria were
excluded from the study: history of hysterectomy and other genital
tract surgery in the three months prior to the screening visit; never
having had penetrative vaginal intercourse; enrolled in HIV
prevention trials involving investigational products; confirmed
internal and/or external genital warts at screening and/or
enrolment; breastfeeding or less than 6 months post-partum at
the time of enrolment; or pregnant (unless for inclusion in the
pregnant women group).
Study procedures
Women who expressed an interest in participating in the study
were asked twice for their written informed consent: first, to be
screened for eligibility for study participation and second, to
participate prior to enrolment. Diagnostic testing was performed
at the screening visit only and consisted of the following tests: HIV,
HSV-2, syphilis, Neisseria gonorrhoea, Chlamydia trachomatis,
Trichomonas vaginalis, urinary tract infection (UTI), pregnancy,
cervical dysplasia screening by Pap smear, BV based on the Amsel
criteria, and vaginal candidiasis. Treatment to participants was
provided according to local standard operational procedures based
on national guidelines. Firstly, symptomatic women with positive
microscopy results for trichomoniasis, BV (by Amsel criteria), and
candidiasis were treated at the screening visit and secondly,
women testing positive for syphilis, trichomoniasis, N. gonorrhoea,
and/or C. trachomatis received treatment at the result visit. STI/
RTI testing was not routinely repeated at enrolment but was
available for women presenting with symptoms. Women received
voluntary HIV counselling and testing according to national
guidelines, and condoms were provided free-of-charge at all visits.
Participants who refused to know their HIV status were ineligible.
Ineligible participants were offered diagnostic testing for vaginal
infections and screening for cervical cancer. Curable RTIs and
UTIs were treated at the study clinics, while women with
abnormal Pap smear, HIV-positive women and pregnant women
were referred to appropriate local public clinics.
At both visits, women were interviewed about their general and
sexual health. A physical and speculum examination was carried
out, and blood and vaginal/endocervical samples were collected.
Ascertainment of BV for research purposes was performed with
Gram stain Nugent scoring by staff at the Institute of Tropical
Medicine in Antwerp for the screening and enrolment visits. At
enrolment a specific set of specimens for the ‘characterisation of
the vagina’ was obtained from each participant including the
Gram stain for BV, a vaginal pH measurement and prostate
specific antigen (PSA).
Correlates of Bacterial Vaginosis in Sub-Saharan Africa
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Laboratory methods
Women in all sites were tested for HIV using a serial testing
algorithm including rapid simple tests. All sites used the Determine
HIV-1/2 (Abbott Diagnostic Division, Hoofddorp, The Nether-
lands) as a first test. In case this was reactive, the specimen was
tested using the SD Bioline (Standard Diagnostics Inc., Kyonggi-
do, South Korea) in Kigali and Mombasa or the Uni-Gold HIV
(Trinity, Berkeley Heights, New Jersey, USA), in Johannesburg.
The latter test was used as a tiebreaker test in Kigali and
Mombasa. In Johannesburg an ELISA 4th generation assay
(Abbott Diagnostic Division, Hoofddorp, The Netherlands) was
employed. HSV-2 antibodies were detected using a HSV-2 IgG
ELISA (Kalon Biologicals, Aldershot, United Kingdom). Syphilis
serology was assessed with RPR (Spinreact (Spinreact Reactivos,
Girona, Spain)) in Kigali, BD Macro-Vue (Becton, Dickinson and
Co, Maryland, USA) in Mombasa and Johannesburg, followed by
TPPA (Serodia-TP.PA (Fujirebio Diagnostics, Pennsylvania,
USA.)). Endocervical swabs were used to test for C. trachomatis
and N. gonorrhoeae by real-time PCR (Abbott Realtime CT/NG
(Abbott Diagnostic Division, Hoofddorp, The Netherlands)),
Diagenode CT/NG RT_PCR (Lie`ge, Belgium), BD ProbeTec
CT/NG (Becton, Dickinson and Co, Maryland, USA) in Rwanda,
Mombasa and Johannesburg, respectively.
A microscopic assessment of a wet mount was performed to
visualise Candida cell budding and hyphae, T. vaginalis and clue
cells. T. vaginalis was cultured using InPouch culture pouches
with assessments at 3 and 5 days after inoculation (Biomed
Diagnostics, Orlando, USA). BV was diagnosed by Amsel criteria
for diagnosis and immediate treatment. For the research project
and data analysis Nugent scoring of Gram stained smears was
performed off-site by 2 experienced laboratory technicians at the
Institute of Tropical Medicine. A score 0–3 was normal (BV-
negative); a score 4–6 meant intermediate microbiota; and score
7–10 was BV positive. Urine was tested for pregnancy by rapid
hCG test and for infection using a urinalysis dipstick. The vaginal
pH was measured using pH 3.6–6.1 paper strips pressed against
the vaginal wall during the pelvic examination (Macherey-Nagel
pH Fix 3.6–6.1, Du¨ren, Germany). Vaginal swab material was
eluted and tested for the presence of PSA using the Seratec PSA
semiquant assay (Seratec Diagnostica, Go¨ttingen, Germany).
Data analysis
We describe here the prevalence of BV and RTIs and correlates
of BV and RTIs among women who were enrolled. This was done
separately for the screening visit and for the enrolment visit. The
reason for this is that women, who were found to have BV or a
treatable RTI at screening, were treated and may have been cured
by the time they were enrolled into the study. For the correlates of
BV and RTI at screening, data on sexual behaviour were used that
were collected at the enrolment visit. For the correlates of BV at
the enrolment visit, the RTI status at the screening visit was used.
Study population characteristics and data on reproductive
health are described as means with ranges for continuous variables
and counts and percentages for categorical variables. A composite
variable was a-priori defined for sexual risk taking. Women were
considered as ‘‘low risk’’ if they had less than 2 partners in the last
year and in the last 3 months did not have any partner who had
multiple partners and were over 14 years old at sexual debut.
‘‘Medium risk’’ was defined as 2 partners in the last year or in the
last 3 months at least one sexual partner who had multiple
partners. Women were considered at ‘‘high risk’’ if they were sex
workers or had at least 3 partners in the last year or had at least
one sexual partner with HIV in the last 3 months or had their
sexual debut before age 15.
No formal statistical testing of between-group differences in
baseline characteristics was performed. When determining corre-
lates of BV, vaginal candidiasis, and RTIs using logistic regression
modelling, a list of potential correlates was defined a-priori based
on clinical and biological relevance. The variable ‘‘recent
antibiotic use’’ was defined as recently started systemic antibiotics
that had been used in the 14 days before the enrolment visit. We
did not include antibiotic treatment for opportunistic infections
because of collinearity with HIV-status. When more than one
treatment was initiated in the 14 days prior to enrollment the
longest treatment was chosen. Bivariable associations were
assessed between each of the potential correlates and BV (defined
as a Nugent score of 7–10 versus Nugent score 0–6) at the
screening and enrolment visits, as well as vaginal candidiasis and
RTIs at the screening visit. Factors significant at p#0.100 were
included in multivariable models which were simplified through
stepwise deletion until all factors were independently associated
with BV, vaginal candidiasis or RTIs at p#0.050 [7]. The final
model was summarised using adjusted odds-ratio, 95% confidence
intervals and p-values. The dataset is available as Table S1.
Ethics statement
All interviews were conducted by a qualified person identified
by the Principal Investigator and done in the language chosen by
the participants. Written information and consent forms in the
local language were provided to the women or legally authorized
representatives for their review. After the interview, the partici-
pants and, in case they were of minor age/not emancipated (age
below 18 in South Africa and Kenya and below 21 in Rwanda),
the parents or guardians were asked to confirm their willingness to
participate in the study by signing (or thumb-printing whenever
they are illiterate) the consent form. The protocol was approved by
the Kenyatta National Hospital Ethical Review Committee,
Kenya; the Human Research Ethics Committee (Medical),
University of the Witwatersrand, SA; the Rwanda National Ethics
Committee, Rwanda; the Institutional Review Board of the
Institute of Tropical Medicine in Antwerp, Ghent University, and
the University Teaching Hospital in Antwerp, Belgium. In
addition the study was approved by the National Council on
Science and Technology in Kenya; the SA Department of Health;
and the National AIDS Control Commission in Rwanda.
Results
A total of 595 women were screened and 430 were enrolled in
the study: 219 in the reference group; 60 pregnant women; 60
adolescents; 31 women engaging in vaginal practices; 30 FSW;
and 30 HIV-positive women. Figure 1 presents the screening and
enrolment flow diagram, including reasons for screening failure.
The median time between the screening and enrolment visits was
25 days (interquartile range 14–39 days).
Sociodemographic, behavioural, and clinical
characteristics
The mean ages were similar across the groups (25–26 years),
except for the adolescents (16 years) and the HIV-positive women
(30 years) (Table 1). Most adolescents and the majority of FSW
and women in SA were not married. The educational level was
highest in SA and lowest in Rwanda.
Age at first sexual intercourse was lower for the adolescents
compared to the other groups, as sexual activity was an inclusion
criterion for all women in the study. Kenyan women in the
reference group, and adolescents in Kenya and SA, were less likely
to have had three or more lifetime sex partners than women in the
Correlates of Bacterial Vaginosis in Sub-Saharan Africa
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other groups (Table 1). Adolescents were less likely to report a
(new or old) sex partner in the 3 months preceding the enrolment
visit. The estimated frequency of sexual intercourse was highest for
pregnant women and lowest for adolescents. FSW, HIV-positive
women and adolescents reported the highest use of condoms.
Nineteen percent of women in the vaginal practices group used
vaginal drying or tightening products before sex. Vaginal cleansing
after sex was practiced by 90% of these women but was also a
common practice among women in the other study groups.
Vaginal washing as part of bathing was frequently reported by all
groups although pregnant women reported somewhat less washing
of the vagina. Women mostly inserted water and/or soap using
their fingers, and women in the vaginal practices group also used
cloth (74%) and lemon juice and/or detergents (23%). Nearly all
women in Kenya reported that their partners of the past three
months were circumcised compared to only half of the women in
Rwanda and SA.
Use of antibiotics
Systemic antibiotics, excluding treatment for opportunistic
infection (26 women), were used by 62 women (14%), during
the last 14 days before the enrolment visit. The last day of
antibiotic use was on average 7 days (median 7 days) prior to the
enrolment visit. Antibiotics were prescribed for 17 cases of BV (by
Amsel criteria), 12 cases of C. trachomatis, 10 pelvic inflammatory
disease cases, six cases of trichomoniasis, four cases of N.
gonorrhoea, two syphilis infections, one ulcer disease infection,
five respiratory infections, two urinary tract infections, and three
other indications.
Reproductive health characteristics
Use of contraceptives was lowest among adolescents. The most
commonly used contraceptive methods were condoms and/or
progestin-only injections but among adolescents the most used
method was by far condoms (Table 1).
Unusual vaginal discharge on speculum examination was
frequently observed despite the low reporting of vaginal discharge
by the study participants themselves. At visual inspection with
speculum examination only few large areas of ectopy were
diagnosed, but moderate areas of ectopy were more common, in
particular among FSW and HIV infected women.
The mean vaginal pH was 4.7 (standard deviation (SD) = 0.7)
with the majority (68%) of women having a vaginal pH between
four and five. Ten percent of women had a pH below four (data
not shown).
Prevalence of reproductive tract infections
RTIs were common (Table 1), especially HSV-2 infection with
prevalence rates ranging from 3% in South African adolescents to
83% in HIV-positive women. T. vaginalis and C. trachomatis
prevalence rates were highest in the vaginal practices group (13%
and 26%, respectively). N. gonorrhoea and syphilis were not
common except in FSW (7% and 7%) and HIV-positive women
(13% and 20%). Candida species were detected in 57% of the
pregnant women in SA and 3–37% of the women in the other
groups.
Prevalence of BV by Nugent score
Nugent scores were available for 394/430 (92%) women at
screening and for 389/430 (90%) women at enrolment. For the
remaining women, slides were unavailable (2/3, at screening/
enrolment), inadequate (8/10) or could not be read due to the
absence of bacteria (24/26) or presence of Streptococcus cell type
(2/2). Of the scored smears, 38% (n= 148) had a Nugent score of
7–10 and 10% a Nugent score of 4–6 at screening. At enrolment,
36% (n= 139) had a Nugent score of 7–10 and 7% of 4–6. One in
four of the BV scores at enrolment were incident cases of BV by
Nugent score. The other 75% had BV by Nugent score at
screening and at enrolment. The prevalence of BV at enrolment
Figure 1. Recruitment flow chart. This Figure presents the screening and enrolment flow diagram, including reasons for screening failure. A total
of 595 women were screened and 430 were enrolled in the study: 219 in the reference group; 60 pregnant women; 60 adolescents; 31 women
engaging in vaginal practices; 30 FSW; and 30 HIV-positive women. ICRHK: International Centre of Reproductive Health, Mombasa, Kenya; RU: Rinda
Ubuzima, Kigali, Rwanda; WrHI: Wits Reproductive Health and HIV Institute, Johannesburg, South Africa. Other ineligibility reasons: moving out of the
area; not able to keep appointments due to mobility; unknown. Vaginal practices: Using traditional vaginal practices with anything other than water,
soap and/or fingers alone.
doi:10.1371/journal.pone.0109670.g001
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was highest in the FSW (68%) and HIV-positive women (48%)
(Table 1 and Figure 2).
Correlates of BV by Nugent score
Bivariable and multivariable logistic regression modelling of
correlates of BV (Nugent score 7–10) at screening and at
enrolment are presented in Table 2. At screening, the use of
progestin-only contraception was associated with a lower preva-
lence of BV (OR 0.57; CI: 0.35–0.93), while the presence of more
than one RTI was associated with a higher prevalence of a BV
score (OR 5.07; CI: 1.32–19.5). Both associations remained
statistically significant (p#0.05) in the multivariable model.
At enrolment, the associations with being a self-acknowledged
FSW (AOR 4.31; CI: 1.79–10.39) and recent unprotected sex as
evidenced by the presence of PSA in vaginal fluid (AOR 2.35; CI:
1.52–3.63) were statistically significant (p#0.05) in the multivar-
iable model. Other factors that were associated with a BV score at
p#0.10 in bivariable analysis were: study site, recent antibiotic
use, positive HSV-2 serology, and having more than one RTI
(other than candidiasis, HIV or HSV-2 infection) at screening,
having had more than one lifetime sex partner, and having had
more than one sex partner in the past three months. FSW more
often presented with incident BV by Nugent score at enrolment
compared to the other women (AOR 4.69; CI: 1.44–15.2). No
significant difference was seen for persistent BV by Nugent score at
both visits between FSW and the other women. On the other
hand, PSA presence was strongly related to persistent BV (AOR
2.22; CI: 1.36–3.62).
Correlates of vaginal candidiasis and RTIs at screening
The prevalence of Candida species was higher in SA (adjusted
odds ratio (AOR) 3.88; CI: 2.22–6.78) and in pregnant women
(AOR 2.98, CI: 1.60–5.55) (Table 3). The likelihood of any RTI
(syphilis, N. gonorrhoea, C. trachomatis, T. vaginalis) was lower
when married (AOR 0.31; CI: 0.15–0.67) and when having lived
at the same address for more than 12 months (AOR 0.51, CI:
0.27–0.98), but higher when engaging in vaginal practices (water/
fingers AOR 2.87; CI 1.33–6.17; water and soap AOR 3.47; CI
1.37–8.78; cloth/substances AOR 3.34; CI: 1.33–8.38), the
presence of ectopy (AOR 2.58; CI 1.39–4.80), positive HIV status
(AOR 2.29; CI: 1.04–8.23), and vaginal dysbiosis (BV: AOR 3.14;
CI: 1.66–5.94; intermediate microbiota: AOR 3.16; CI: 1.26–
7.88). Positive HSV-2 serology was more common among women
who were older than 30 (AOR 4.97; CI: 1.42–17.44), had given
birth (1–2 children AOR 2.89; CI: 1.51–5.54; .2 children AOR
3.04; CI: 1.29–7.15), had had more than three lifetime sex
partners (AOR 5.33; CI: 2.58–10.99), and were HIV infected
(AOR 5.77; CI: 2.03–16.42). Women who had lived at the same
address for more than 12 months were less likely to have positive
HSV-2 serology (AOR 0.43; CI: 0.24–0.75).
Discussion
The main objective of our project was to characterise the
vaginal environment in a reference group of women and in
different groups of African women who would be recruited in trials
of biomedical interventions or would be targeted for such
interventions. As such we recruited women through reproductive
health services and from selected communities. In most groups of
women the prevalence of BV was in the range of 30 to 40%,
except for adolescent girls who had a lower prevalence and FSW
and HIV infected women who had a higher prevalence. There are
some data available on the prevalence of BV in similar populations
and sites but comparing prevalence rates is challenging. Previous
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studies conducted among pregnant women in KwaZulu Natal
(South-Africa) found prevalence rates of over 50% [8] which is
substantially higher than in our study but it should be noted that
we excluded HIV infected pregnant women. Among a sample of
40 adult women attending a perinatal clinic in Johannesburg 35%
were found to have BV as assessed by Nugent score which is in line
with our findings [9]. Among FSW in Mombasa the prevalence of
BV was lower than among the FSW in Kigali in our study [10].
Possible explanations for this difference could be more intensive
follow-up of the FSW in Mombasa with frequent treatment and/
or the fact that men in Mombasa are more frequently circumcised
than men in Kigali [10].
At the screening visit, i.e. before any antibiotic treatment for
symptomatic BV, RTIs or other infections were given, BV was
associated in a multivariable analysis with the presence of more
than one other RTI (syphilis, trichomoniasis, gonorrhoea,
chlamydial infection) and with the use of progestin-only contra-
ception. As this was a cross-sectional study it is not possible to
ascertain the temporal relationship between BV and other RTIs.
There is some evidence that other RTIs are risk factors for BV
[11] and that BV enhances the vulnerability of women to other
RTIs [12–14]. Our finding of an association between BV and use
of progestin-only contraception is in agreement with two
longitudinal studies that found hormonal contraception to be
protective against BV [15,16].
At the enrolment visit BV was associated with being a sex
worker and with having had sexual intercourse recently, as
evidenced by the presence of PSA in cervicovaginal fluid.
The presence of PSA is indicative of unprotected sexual
intercourse within 14 up to 72 hours before sampling. The strong
association we found between BV and presence of PSA adds to the
evidence that exposure to vaginal penetration and male seminal
plasma deposition contributes to the development and sustainment
of BV. In a study of a large series of Papanicolaou smears taken
before and after unprotected coitus, it was observed that
lactobacilli-dominated precoital smears were replaced by G.
vaginalis dominant microbiota in postcoital smears [17]. Another
study showed that having had sex within the past 24 hours
compared to more than a week ago increased the Nugent score
significantly [18]. The most straightforward explanation for this is
that unprotected sexual intercourse alters the physico-chemical
vaginal environment thereby also affecting the vaginal microbiota.
At enrolment being a FSW was strongly related to having a BV
score. Further, several sexual behavioural factors were associated
in bivariable analysis: having had more than one lifetime sex
partner, having had more than one sex partner in the past three
months, positive HSV-2 serology, and having more than one RTI
(other than candidiasis, HIV or HSV-2 infection) at screening.
The fact that a BV score was associated with FSW status at
enrollment, but not at screening may be a chance finding or
Figure 2. The prevalence of Bacterial Vaginosis at screening and at enrolment. The prevalence of BV at enrolment was highest in female
sex workers (68%) and HIV-positive women (48%) in Rwanda. Black bar: Nugent score 7–10 classified as BV; Grey bar: Nugent score 4–6 classified as
intermediate; White bar: Nugent score 0–3 classified as normal. Groups: R = Reference group, P = Pregnant women, A = adolescents, V = vaginal
practices, FSW= female sex worker, and HIV+= HIV-positive women.
doi:10.1371/journal.pone.0109670.g002
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Table 2. Correlates of bacterial vaginosis at the screening and enrolment visit - bivariable and multivariable models.
BV1 at screening (37.6%) BV1 at enrolment (35.7%)
Unadjusted Adjusted2 Unadjusted Adjusted
N=394 OR (CI) OR (CI) N=389 OR (CI) OR (CI)
Site % (p=0.250) % (p=0.002)
Kenya 32.5 Ref. 31.8 Ref
Rwanda 40.0 1.39 (0.73, 2.63) 57.7 2.92 (1.53, 5.58)
South Africa 41.0 1.44 (0.92, 2.26) 32.0 1.01 (0.64, 1.60)
Age category (p = 0.337) (p = 0.632)
,18 years 39.7 Ref 30.4 Ref
18–24 years 42.8 1.14 (0.61, 2.12) 36.5 1.32 (0.68, 2.57)
25–29 years 32.3 0.73 (0.38, 1.38) 34.4 1.20 (0.61, 2.36)
30 years or more 35.2 0.83 (0.40, 1.69) 41.2 1.61 (0.76, 3.39)
Marital Status (p = 0.196) (p = 0.897)
Never married 40.3 Ref 36.3 Ref
Married 35.8 0.83 (0.53, 1.29) 34.3 0.92 (0.59, 1.43)
Sep/Div/Wid 24.1 0.47 (0.19, 1.15) 37.9 1.07 (0.48, 2.38)
Education (P-value = 0.619) (P-value = 0.670)
None/Some prim 38.9 Ref 41.2 Ref
Prim/Some sec 34.8 0.84 (0.44, 1.58) 35.5 0.79 (0.41, 1.50)
Sec/Higher 39.8 1.04 (0.56, 1.94) 34.3 0.75 (0.39, 1.42)
Living at current address (p = 0.377) (p = 0.423)
0–12 months 41.6 Ref 39.3 Ref
.12 months 36.4 0.80 (0.50, 1.30) 34.7 0.82 (0.50, 1.33)
Parity (p = 0.702) (p = 0.535)
0 39.9 Ref 32.1 Ref
1–2 35.5 0.83 (0.53, 1.30) 37.9 1.29 (0.82, 2.04)
.2 38.9 0.96 (0.51, 1.82) 37.0 1.24 (0.64, 2.39)
Early pregnancy3 (p = 0.675) (p = 0.308)
No 38.0 Ref 36.7 Ref
Yes 35.1 0.88 (0.49, 1.59) 29.8 0.73 (0.40, 1.35)
Contraception (p =0.063)9 (p = 0.020)9 (p = 0.794)
None/Non-Horm 41.1 Ref Ref 37.0 Ref
Progesteron only 28.6 0.57 (0.35, 0.93) 0.51 (0.31, 0.84) 33.3 0.85 (0.53, 1.37)
Combined Horm 41.5 1.02 (0.52, 1.99) 1.06 (0.54, 2.09) 34.8 0.91 (0.47, 1.76)
Recent systemic antibiotic use4 (p =0.075)
No NA 33.9 Ref
Yes NA 46.4 1.69 (0.95, 2.99)
Sex worker (p = 0.725) (p#0.001) (p#0.001)
No 37.3 Ref 33.3 Ref Ref
Yes 40.7 1.15 (0.52, 2.56) 69.2 4.50 (1.90,10.64) 4.31 (1.79,10.39)
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Table 2. Cont.
BV1 at screening (37.6%) BV1 at enrolment (35.7%)
Unadjusted Adjusted2 Unadjusted Adjusted
N=394 OR (CI) OR (CI) N=389 OR (CI) OR (CI)
Site % (p=0.250) % (p=0.002)
Lifetime sex partners (p = 0.469) (p = 0.044)
1 38.8 Ref 25.7 Ref
2–3 34.3 0.82 (0.50, 1.36) 38.4 1.80 (1.05, 3.09)
.3 41.2 1.10 (0.64, 1.89) 40.5 1.97 (1.10, 3.53)
Sex partners last 3 months (p = 0.283) (p = 0.006)
0 22.7 Ref 16.7 Ref
1 38.1 2.09 (0.75, 5.80) 34.9 2.68 (0.89, 8.02)
.1 41.5 2.41 (0.74, 7.80) 55.3 6.18 (1.77, 21.55)
Condom use last sexual contact (p = 0.757) (p = 0.345)
No 37.1 Ref 34.3 Ref
Yes 38.8 1.07 (0.69, 1.68) 39.4 1.25 (0.79, 1.96)
Circumcision status partners (p = 0.934) (p = 0.291)
Not circumcised 37.9 Ref 41.0 Ref
Circumcised 37.4 0.98 (0.61–1.59) 34.8 0.77 (0.47–1.25)
Frequency of sexual intercourse in
the past 3 months
(p = 0.702) (p = 0.373)
Up to 10 times 39.1 Ref Ref
11–30 times 38.4 0.97 (0.59–1.61) 1.23 (0.73–2.06)
.30 times 33.7 0.79 (0.45–1.40) 0.82 (0.46–1.44)
Recent vaginal sex at enrolment5 (p = 0.113)
No NA 33.9 Ref
Yes NA 43.8 1.52 (0.91, 2.56)
PSA present at enrolment6 (p#0.001)9
No NA 27.3 Ref Ref
Yes NA 47.3 2.39 (1.56, 3.66) 2.35 (1.52, 3.63)
Wash inside vagina7 (p = 0.138) (p = 0.418)
No 42.9 Ref 39.4 Ref
Yes 35.1 0.72 (0.47, 1.11) 30.8 0.68 (0.35, 1.34)
Yes, recently NA 33.9 0.79 (0.51–1.23)
Products used inside vagina (p = 0.416) (p = 0.503)
None 42.3 Ref 38.0 Ref
Water/fingers 37.5 0.82 (0.50, 1.34) 38.7 1.03 (0.63, 1.70)
Water and soap 31.8 0.64 (0.34, 1.18) 30.6 0.72 (0.39, 1.32)
Cloth/Substances 32.8 0.67 (0.35, 1.26) 30.4 0.71 (0.37, 1.39)
HIV (p = 0.825) (p = 0.177)
No 37.8 Ref 35.0 Ref
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alternatively at screening the contrast between FSW and other
women may be smaller because of untreated RTIs in the non-
FSW population. As FSW are more likely to seek treatment on a
more regular basis. It may also be partially due to the significant
higher number of new cases of incident BV in the FSW group
compared to the other women. New RTI infections and the high
HSV-2 prevalence in this highly sexually active group could have
led to a higher incidence of BV. As we did not routinely retest for
RTIs at the enrolment we can’t exclude new infections at this visit
which may have caused shifts in microbiota composition.
In our study we could not find a statistically significant
association between BV and a number of sexual behavioural risk
factors that were documented in other studies, including higher
numbers of lifetime sex partners, lack of condom use and
frequency of sexual intercourse [19]. There was also hardly any
difference in prevalence of BV between women who reported that
their male partners were circumcised compared to women who
had sexual intercourse with uncircumcised men whereas Gray et al
found that circumcision of male partners is protective against BV
[10]. We attribute this to the low power of our study. Although the
overall sample size was high, the sample size in each sub-
population was rather low.
We did not find vaginal washing to be associated with BV,
neither at screening nor at enrolment. Some studies have found
douching and vaginal practices to be associated with BV but
others could not confirm this [20]. Interestingly we found an
association between vaginal washing and other RTIs. However it
is not clear whether vaginal washing increases the susceptibility to
these RTIs or whether women more frequently wash the vagina
inside when they become symptomatic with RTIs.
We encountered several limitations in the study. An important
limitation in the analysis was the use of data from the screening
visit for the analysis at enrolment. The following data was collected
at screening: RTIs (CT, NG, TV, HSV-2 and syphilis), which
were not re-tested at enrolment, and the data of number of lifetime
sex partners and number of sex partners in the past three months.
Still, we believe that the main finding of the paper, the association
of PSA and BV, is not affected by this shortcoming. For the
laboratory testing, some cases of candidiasis may have been missed
because diagnostic laboratory testing for Candida relied on
microscopic evaluation and did not include culture. The diagnosis
of T. vaginalis was performed by InPouch culture instead of
nucleic acid amplification testing, which was not available to us at
the time of our study. However, the sensitivity of InPouch culture
when the culture is assessed after five days is 94% compared to
nucleic acid amplification testing.
In conclusion, our study confirmed some of the correlates of BV
that have been found in other studies but the most salient finding
was the association between BV and the presence of PSA in the
cervicovaginal fluid. A detailed characterisation of the vaginal
microbiota will allow us to explore this association in more detail.
Table 2. Cont.
BV1 at screening (37.6%) BV1 at enrolment (35.7%)
Unadjusted Adjusted2 Unadjusted Adjusted
N=394 OR (CI) OR (CI) N=389 OR (CI) OR (CI)
Site % (p=0.250) % (p=0.002)
Yes 35.7 0.91 (0.41, 2.04) 48.1 1.72 (0.79, 3.78)
HSV-2 (p = 0.504) (p = 0.086)
No 36.4 Ref 32.7 Ref
Yes 39.8 1.16 (0.75, 1.78) 41.5 1.46 (0.95, 2.25)
Vaginal Candidiasis (p = 0.770) 0.044
No 38.0 Ref 38.3 Ref
Yes 36.3 0.93 (0.57, 1.51) 26.7 0.59 (0.35, 1.00)
RTIs8 (p =0.007) (p = 0.002) (p = 0.033)
No RTIs 34.5 Ref Ref 33.0 Ref
1 RTI 49.1 1.83 (1.03, 3.26) 1.89 (1.05, 3.38) 48.1 1.88 (1.04, 3.39)
.1 RTIs 72.7 5.07 (1.32, 19.5) 6.80 (1.71, 27.1) 60.0 3.04 (0.84, 11.0)
BV = bacterial vaginosis; Horm = hormonal; HSV-2 = herpes simplex virus type 2; NA= not applicable; OR = odds ratio; CI = confidence interval; Prim = primary
education; PSA = prostate specific antigen; Ref = reference category; RTI = reproductive tract infection; Sec = secondary education; Sep/Div/Wid = separated,
divorced or widowed.
1BV as defined by Nugent score: for the analysis we classified BV-Positive Nugent 7–10 versus BV-Negative Nugent 0–6;
2Bolded p-values indicate significant associations at the level p#0.100 for the bivariable analysis and were selected for multivariable modelling. Adjusted odd-ratios are
only shown for factors which remained statistically significant at p#0.050 level after stepwise deletion.
3Early pregnancy: gestation less than 14 weeks;
4Antibiotic use within the last 14 days;
5Recent vaginal sex: vaginal sex this morning and/or yesterday evening (only recorded at enrolment visit);
6Presence of PSA a marker of semen in vaginal fluid;
7Wash vagina at screening: When you bathe, do you wash inside the vagina? Recently (only recorded at enrolment visit): this morning and/or yesterday evening;
8Includes: syphilis, Neisseria gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis.
9Associations remain statistically significant in the non-pregnant women group (N= 219).
doi:10.1371/journal.pone.0109670.t002
Correlates of Bacterial Vaginosis in Sub-Saharan Africa
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e109670
T
a
b
le
3
.
C
o
rr
e
la
te
s
o
f
re
p
ro
d
u
ct
iv
e
tr
ac
t
in
fe
ct
io
n
s
at
th
e
sc
re
e
n
in
g
vi
si
t
-
b
iv
ar
ia
b
le
an
d
m
u
lt
iv
ar
ia
b
le
m
o
d
e
ls
.
V
a
g
in
a
l
C
an
d
id
a
1
(2
2
.1
%
)
A
n
y
o
f
sy
p
h
il
is
,
N
.
g
o
n
o
rr
h
o
e
a,
C
.
tr
ac
h
o
m
at
is
o
r
T
.
va
g
in
al
is
2
(1
7
.0
%
)
H
S
V
-2
(3
4
.3
%
)
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
N
=
4
3
0
O
R
(C
I)
O
R
(C
I)
N
=
4
3
0
O
R
(C
I)
O
R
(C
I)
N
=
4
2
9
O
R
(C
I)
O
R
(C
I)
S
it
e
%
(p
=
,
.0
0
1
)4
(p
=
,
.0
0
1
)4
%
(p
,
.0
0
1
)
%
(p
,
.0
0
1
)
K
e
n
y
a
1
2
.4
R
e
f
R
e
f
8
.8
2
R
e
f
2
2
.9
R
e
f
R
w
a
n
d
a
1
1
.7
0
.9
4
(0
.3
8
,
2
.3
3
)
1
.2
2
(0
.4
8
,
3
.1
0
)
2
6
.7
3
.7
6
(1
.7
2
,
8
.2
0
)
6
4
.4
6
.0
8
(3
.2
0
,1
1
.5
5
)
S
o
u
th
A
fr
ic
a
3
3
.5
3
.5
7
(2
.0
8
,
6
.1
5
)
3
.8
8
(2
.2
2
,
6
.7
8
)
2
1
.0
2
.7
5
(1
.4
6
,
5
.1
6
)
3
5
.0
1
.8
1
(1
.1
4
,
2
.8
7
)
A
g
e
ca
te
g
o
ry
(p
=
0
.9
4
4
)
(p
=
0
.5
1
0
)
(p
,
.0
0
1
)
(p
=
0
.0
0
4
)
,
1
8
y
e
a
rs
2
0
.0
R
e
f
1
3
.3
R
e
f
6
.6
7
R
e
f
R
e
f
1
8
–
2
4
y
e
a
rs
2
3
.5
1
.2
3
(0
.5
9
,
2
.5
7
)
2
0
.1
1
.6
4
(0
.7
0
,
3
.8
2
)
2
2
.1
3
.9
8
(1
.3
4
,1
1
.7
9
)
1
.5
4
(0
.4
8
,
4
.9
4
)
2
5
–
2
9
y
e
a
rs
2
2
.1
1
.1
4
(0
.5
4
,
2
.4
0
)
1
7
.1
1
.3
4
(0
.5
7
,
3
.1
9
)
4
3
.6
1
0
.8
1
(3
.7
2
,3
1
.4
5
)
2
.9
3
(0
.9
0
,
9
.5
4
)
3
0
o
r
m
o
re
2
1
.0
1
.0
6
(0
.4
6
,
2
.4
3
)
1
3
.6
1
.0
2
(0
.3
8
,
2
.7
2
)
6
1
.3
2
2
.1
3
(7
.3
0
,6
7
.1
2
)
4
.9
7
(1
.4
2
,1
7
.4
4
)
M
a
ri
ta
l
S
ta
tu
s
(p
=
0
.2
5
4
)
(p
=
0
.0
0
2
)4
(p
=
0
.0
0
5
)4
(p
=
0
.0
0
2
)
N
e
v
e
r
m
a
rr
ie
d
2
3
.6
R
e
f
2
1
.1
R
e
f
R
e
f
2
8
.0
R
e
f
M
a
rr
ie
d
2
2
.0
0
.9
1
(0
.5
6
,
1
.4
9
)
8
.6
7
0
.3
5
(0
.1
9
,
0
.6
8
)
0
.3
1
(0
.1
5
,
0
.6
7
)
3
9
.6
1
.6
8
(1
.0
9
,
2
.5
9
)
S
e
p
/D
iv
/W
id
1
1
.8
0
.4
3
(0
.1
5
,
1
.2
8
)
2
3
.5
1
.1
5
(0
.4
9
,
2
.6
8
)
0
.8
5
(0
.2
9
,
2
.5
0
)
5
5
.9
3
.2
5
(1
.5
6
,
6
.7
6
)
L
iv
in
g
a
t
C
u
rr
e
n
t
A
d
d
re
ss
(p
=
0
.4
2
2
)
(p
=
0
.0
3
4
)
(p
=
0
.0
4
5
)
(p
=
0
.0
5
4
)
(p
=
0
.0
0
3
)
0
–
1
2
m
o
n
th
s
1
9
.2
R
e
f
2
4
.2
R
e
f
R
e
f
4
2
.4
R
e
f
R
e
f
.
1
2
m
o
n
th
s
2
3
.0
1
.2
5
(0
.7
2
,
2
.2
0
)
1
4
.8
0
.5
4
(0
.3
1
,
0
.9
4
)
0
.5
1
(0
.2
7
,
0
.9
8
)
3
1
.8
0
.6
3
(0
.4
0
,
1
.0
0
)
0
.4
3
(0
.2
4
,
0
.7
5
)
P
a
ri
ty
(p
=
0
.1
0
4
)
(p
=
0
.9
3
9
)
(p
=
,
.0
0
1
)4
(p
=
0
.0
0
4
)
0
2
7
.5
R
e
f
1
6
.1
R
e
f
1
3
.4
R
e
f
R
e
f
1
–
2
2
0
.3
0
.6
7
(0
.4
1
,
1
.0
9
)
1
7
.5
1
.1
1
(0
.6
3
,
1
.9
4
)
4
2
.9
4
.8
4
(2
.8
1
,
8
.3
2
)
2
.8
9
(1
.5
1
,
5
.5
4
)
.
2
1
5
.6
0
.4
9
(0
.2
3
,
1
.0
5
)
1
7
.2
1
.0
8
(0
.4
9
,
2
.3
6
)
5
4
.0
7
.5
6
(3
.8
2
,1
4
.9
8
)
3
.0
4
(1
.2
9
,
7
.1
5
)
S
e
x
w
o
rk
e
r
(p
=
0
.0
7
3
)
(p
=
0
.3
5
6
)
(p
=
0
.0
6
6
)
N
o
2
3
.0
R
e
f
1
6
.5
R
e
f
3
3
.1
R
e
f
Y
e
s
1
0
.0
0
.3
7
(0
.1
1
,
1
.2
5
)
2
3
.3
1
.5
4
(0
.6
3
,
3
.7
4
)
5
0
.0
2
.0
2
(0
.9
6
,
4
.2
6
)
L
if
e
ti
m
e
se
x
p
a
rt
n
e
rs
(p
=
0
.4
2
3
)
(P
-v
a
lu
e
=
0
.0
3
5
)
(p
,
.0
0
1
)4
(p
,
.0
0
1
)4
1
2
4
.1
R
e
f
1
4
.3
R
e
f
1
2
.6
R
e
f
R
e
f
2
–
3
2
3
.6
0
.9
7
(0
.5
6
,
1
.6
8
)
1
3
.6
0
.9
5
(0
.4
8
,
1
.8
5
)
3
5
.1
3
.7
4
(1
.9
9
,
7
.0
6
)
2
.7
6
(1
.3
8
,
5
.5
2
)
Correlates of Bacterial Vaginosis in Sub-Saharan Africa
PLOS ONE | www.plosone.org 13 October 2014 | Volume 9 | Issue 10 | e109670
T
a
b
le
3
.
C
o
n
t.
V
a
g
in
a
l
C
an
d
id
a
1
(2
2
.1
%
)
A
n
y
o
f
sy
p
h
il
is
,
N
.
g
o
n
o
rr
h
o
e
a,
C
.
tr
ac
h
o
m
at
is
o
r
T
.
va
g
in
al
is
2
(1
7
.0
%
)
H
S
V
-2
(3
4
.3
%
)
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
3
A
d
ju
st
e
d
N
=
4
3
0
O
R
(C
I)
O
R
(C
I)
N
=
4
3
0
O
R
(C
I)
O
R
(C
I)
N
=
4
2
9
O
R
(C
I)
O
R
(C
I)
S
it
e
%
(p
=
,
.0
0
1
)4
(p
=
,
.0
0
1
)4
%
(p
,
.0
0
1
)
%
(p
,
.0
0
1
)
.
3
1
8
.1
0
.7
0
(0
.3
7
,
1
.3
0
)
2
4
.4
1
.9
4
(1
.0
0
,
3
.7
7
)
5
2
.0
7
.5
0
(3
.8
8
,1
4
.5
0
)
5
.3
3
(2
.5
8
,1
0
.9
9
)
P
ro
d
u
ct
s
u
se
d
in
si
d
e
v
a
g
in
a
(p
=
0
.1
1
3
)
(p
=
0
.0
0
4
)5
(p
=
0
.0
0
9
)4
(p
=
0
.0
1
2
)
N
o
n
e
2
2
.1
R
e
f
9
.0
9
R
e
f
R
e
2
5
.5
R
e
f
W
a
te
r/
fi
n
g
e
rs
1
6
.9
0
.7
2
(0
.4
0
,
1
.2
9
)
2
3
.5
3
.0
8
(1
.5
6
,
6
.0
6
)
2
.8
7
(1
.3
3
,
6
.1
7
)
4
2
.6
2
.1
7
(1
.3
2
,
3
.5
8
)
W
a
te
r
a
n
d
so
a
p
2
2
.8
1
.0
4
(0
.5
4
,
1
.9
9
)
1
6
.5
1
.9
7
(0
.8
8
,
4
.4
3
)
3
.4
7
(1
.3
7
,
8
.7
8
)
3
1
.6
1
.3
5
(0
.7
4
,
2
.4
6
)
C
lo
th
/S
u
b
st
a
n
ce
s
3
2
.8
1
.7
2
(0
.8
9
,
3
.3
2
)
2
3
.0
2
.9
8
(1
.3
2
,
6
.7
0
)
3
.3
4
(1
.3
3
,
8
.3
8
)
4
1
.0
2
.0
3
(1
.0
8
,
3
.8
0
)
E
a
rl
y
p
re
g
n
a
n
cy
5
(p
,
.0
0
1
)
(p
,
.0
0
1
)
(p
=
0
.9
4
5
)
(p
=
0
.1
7
4
)
N
o
1
9
.2
R
e
f
R
e
f
1
7
.0
R
e
f
3
5
.5
R
e
f
Y
e
s
4
0
.0
2
.8
1
(1
.5
8
,
5
.0
0
)
2
.9
8
(1
.6
0
,
5
.5
5
)
1
6
.7
0
.9
7
(0
.4
7
,
2
.0
2
)
2
6
.7
0
.6
6
(0
.3
6
,
1
.2
2
)
H
IV
(p
=
0
.2
1
2
)
(p
=
0
.0
6
9
)
(p
=
0
.0
4
7
)
(p
,
.0
0
1
)
(p
,
.0
0
1
)
N
o
2
2
.6
R
e
f
1
6
.1
R
e
f
R
e
f
3
0
.9
R
e
f
R
e
f
Y
e
s
1
3
.3
0
.5
3
(0
.1
8
,
1
.5
5
)
3
0
.0
2
.2
4
(0
.9
8
,
5
.1
1
)
2
.9
2
(1
.0
4
,
8
.2
3
)
2
4
/2
9
(8
2
.8
)
1
0
.7
3
(4
.0
0
,2
8
.7
9
)
5
.7
7
(2
.0
3
,1
6
.4
2
)
B
V
(p
=
0
.8
8
3
)
(p
,
.0
0
1
)
(p
,
.0
0
1
)
(p
=
0
.0
9
3
)
N
e
g
a
ti
v
e
(0
–
3
)
2
4
.0
R
e
f
9
.6
2
R
e
f
R
e
f
2
9
.8
R
e
f
In
te
rm
e
d
ia
te
(4
–
6
)
2
1
.1
0
.8
4
(0
.3
6
,
1
.9
6
)
2
8
.9
3
.8
3
(1
.6
5
,
8
.8
6
)
3
.1
6
(1
.2
6
,
7
.8
8
)
4
7
.4
2
.1
2
(1
.0
5
,
4
.2
8
)
P
o
si
ti
v
e
(7
–
1
0
)
2
2
.3
0
.9
1
(0
.5
5
,
1
.5
0
)
2
3
.6
2
.9
1
(1
.6
0
,
5
.2
9
)
3
.1
4
(1
.6
6
,
5
.9
4
)
3
5
.8
1
.3
1
(0
.8
4
,
2
.0
6
)
E
ct
o
p
y
o
f
th
e
ce
rv
ix
6
(p
=
0
.3
1
6
)
(p
=
0
.0
0
2
)
(p
=
0
.0
0
2
)
(p
=
0
.0
0
9
)
N
o
2
4
.0
R
e
f
1
1
.8
R
e
f
R
e
f
2
8
.5
R
e
f
Y
e
s
2
0
.0
0
.7
9
(0
.5
0
,
1
.2
5
)
2
3
.0
2
.2
3
(1
.3
3
,
3
.7
6
)
2
.5
8
(1
.3
9
,
4
.8
0
)
4
0
.5
1
.7
1
(1
.1
4
,
2
.5
5
)
B
V
=
b
ac
te
ri
al
va
g
in
o
si
s;
H
SV
-2
=
h
e
rp
e
s
si
m
p
le
x
vi
ru
s;
P
SA
=
p
ro
st
at
e
sp
e
ci
fi
c
an
ti
g
e
n
;
R
e
f
=
re
fe
re
n
ce
ca
te
g
o
ry
;
R
T
I
=
re
p
ro
d
u
ct
iv
e
tr
ac
t
in
fe
ct
io
n
;
Se
p
/D
iv
/W
id
=
se
p
ar
at
e
d
,
d
iv
o
rc
e
d
,
o
r
w
id
o
w
e
d
.
1
V
ag
in
al
C
a
n
d
id
a
as
d
ia
g
n
o
se
d
b
y
w
e
t
m
o
u
n
t
m
ic
ro
sc
o
p
y;
2
8
7
in
fe
ct
io
n
s
in
7
3
w
o
m
e
n
;
3
B
o
ld
e
d
p
-v
al
u
e
s
in
d
ic
at
e
si
g
n
if
ic
an
t
as
so
ci
at
io
n
s
at
th
e
le
ve
lp
#
0
.1
0
0
in
th
e
b
iv
ar
ia
b
le
an
al
ys
is
an
d
w
e
re
se
le
ct
e
d
fo
r
m
u
lt
iv
ar
ia
b
le
m
o
d
e
lli
n
g
.A
d
ju
st
e
d
o
d
d
-r
at
io
s
ar
e
o
n
ly
sh
o
w
n
fo
r
fa
ct
o
rs
w
h
ic
h
re
m
ai
n
e
d
st
at
is
ti
ca
lly
si
g
n
if
ic
an
t
at
p
#
0
.0
5
0
le
ve
l
af
te
r
st
e
p
w
is
e
d
e
le
ti
o
n
.
4
A
ss
o
ci
at
io
n
s
re
m
ai
n
e
d
st
at
is
ti
ca
lly
si
g
n
if
ic
an
t
in
th
e
n
o
n
-p
re
g
n
an
t
w
o
m
e
n
g
ro
u
p
(N
=
2
1
9
).
5
Ea
rl
y
p
re
g
n
an
cy
:
g
e
st
at
io
n
le
ss
th
an
1
4
w
e
e
ks
;
6
Ec
to
p
y
=
ce
rv
ic
al
e
ct
o
p
y;
cl
in
ic
al
ly
o
b
se
rv
e
d
an
d
d
e
fi
n
e
d
as
N
o
=
ab
se
n
t,
an
d
Y
e
s
=
sm
al
l,
m
o
d
e
ra
te
o
r
la
rg
e
.
O
R
:
o
d
d
s
ra
ti
o
;
C
I:
co
n
fi
d
e
n
ce
in
te
rv
al
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
6
7
0
.t
0
0
3
Correlates of Bacterial Vaginosis in Sub-Saharan Africa
PLOS ONE | www.plosone.org 14 October 2014 | Volume 9 | Issue 10 | e109670
Supporting Information
Table S1 Dataset.
(XLS)
Methods S1 Study flowchart – evaluations. This chart
describes the cohort study with visit flow and evaluations. Women
were followed up every two weeks for a total of four visits over two
menstrual cycles (visits 2–5), and again three (visit 6) and six
months later (visit 7). Visits 3, 5, 6 and 7 coincided approximately
with day 9 of the menstrual cycle and visits 2 and 4 with day 23.
For women without a menstrual cycle, the same time structure was
followed.
(DOCX)
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